![Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)]()
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of…
PR NEWSWIRE
About M Fund